Search clinical trials for: 2=Clobetasol propionate foam

Total 410 results

Sultan Abdulhamid Han Training and Research Hospital...

Recruiting

Investigation of the Effect of Central Sensitization (CS) on Steroid Injection Response in Rotator Cuff Lesion (CS)

Subacromial Impingement Syndrome | Central Sensitisation

Turkey
GlaxoSmithKline

Completed

Study HZA106829: Efficacy/Safety Study of Fluticasone Furoate/Vilanterol (GW642444) in Adult and Adolescent Asthmatics

Asthma

United States, Germany, Japan, Romania, Russian Federation, Poland
Chiesi Farmaceutici S.p.A.

Withdrawn

Comparison of Combination of Beclomethasone Dipropionate and Formoterol Fumarate Versus Single Components Assessed by Knemometry and Urinary Cortisol Measurements in Asthmatic Children

Asthma in Children

Denmark
University of Pennsylvania
CrystalGenomics, Inc.

Terminated

Effects of Dual Cyclooxygenase-2 and Carbonic Anhydrase Inhibition

Healthy Volunteers

United States
University Hospital Muenster
Deutsche Krebshilfe e.V., Bonn (Germany)

Unknown

Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents

Myeloid Leukemia

Germany
GlaxoSmithKline

Completed

Spacer Comparison In Adult Asthmatics

Asthma

New Zealand
Bristol-Myers Squibb

Completed

Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care

Chronic Hepatitis C

France, United States, Puerto Rico
Mundipharma Research Limited

Completed

Study to Assess Airway Inflammation Effects of FlutiForm® pMDI Low and High Dose in Adults With Mild to Moderate Asthma (FLT2503)

Asthma

Germany
GlaxoSmithKline

Terminated

Study In Asthma Control

Asthma

Canada
GlaxoSmithKline

Completed

Pharmacovigilance Study to Evaluate Safety of SERETIDE in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline

Completed

Successful Control and Clinical Effectiveness Of SERETIDE(Salmeterol/Fluticasone Propionate) Study In Asthma.(SUCCESS)

Asthma

Korea, Republic of
Dey

Completed

A Study in Healthy Volunteers to Evaluate Serum and Urine Levels of the Investigational Product Versus Comparator.

Healthy

United States
Medical University of Vienna

Completed

Gastric Emptying of High Calorie Liquid Meals

Gastric Emptying

Austria
Kindeva Drug Delivery

Completed

Single Blind Cross-over Dose Response Study in Subjects of Two Inhalers of Salmeterol and Fluticasone Propionate

Healthy

United Kingdom
GlaxoSmithKline

Completed

Repeat Dose Study of Fluticasone Propionate/Salmeterol Versus Fluticasone Propionate + Salmeterol In Asthmatics

Asthma

Germany
GlaxoSmithKline

Completed

An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma

Asthma

United States, Argentina, Germany, Korea, Republic of, Romania, Russian Federation, Spain, Netherlands, Mexico, Brazil, Chile, Czechia
Novartis

Completed

Investigation of the 24 Hour Forced Expiratory Flow in 1 Second (FEV1) Profile of a Single Dose of Indacaterol/Mometasone Delivered Via the TWISTHALER® Device in Adult Patients With Persistent Asthma

Asthma

Germany, Belgium
National Jewish Health

Completed

Sub-Sensitivity to Long-Acting Bronchodilators (LABA)

Asthma

United States
SkyePharma AG

Completed

Single-dose Crossover Study to Compare the Safety and Efficacy of FlutiForm With Fluticasone and Formoterol Concurrently or Alone in Asthma Patients

Asthma

United Kingdom, Ireland
SkyePharma AG

Completed

New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) in Patients With Asthma

Asthma

United Kingdom, Germany, Hungary, Poland, Romania
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma (CONNECT2)

Asthma

United States
Canisius-Wilhelmina Hospital
Kappa Bioscience AS

Completed

Randomized Controlled Clinical Trial to Investigate Effects of Vitamin K2 in COVID-19 (KOVIT)

Covid19

Netherlands
Mardan Medical Complex

Completed

Comparison of 3% Normal Saline Nebulization Versus Steroid Nebulization in the Treatment of Bronchiolitis

Acute Bronchiolitis

Pakistan
GlaxoSmithKline

Completed

A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Argentina, Romania, Ukraine, United States, Chile, Greece, Peru
GlaxoSmithKline

Completed

Outcomes in Patients Taking Fluticasone Propionate/Salmeterol Combination or Other Inhaled Corticosteroids

Asthma
GlaxoSmithKline

Terminated

ADVAIR DISKUS® (Fluticasone Propionate/Salmeterol) Inhaler Versus SEREVENT DISKUS® (Salmeterol) Inhlaer On Inflammatory Cells And Markers In Chronic Obstructive Pulmonary Disease. ADVAIR DISKUS® and SEREVENT DISKUS® Inhalers Are Trademarks of the GSK Group of Companies.

Pulmonary Disease, Chronic Obstructive

United States
GlaxoSmithKline

Completed

Airway Inflammation In Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Estonia, Denmark, Spain, Finland, Slovakia, United Kingdom, Italy, Lithuania
Intech Biopharm Ltd.

Completed

Bioequivalence Study of Synflutide HFA Inhaler and Seretide Evohaler in Healthy Volunteers Without Charcoal Block

Asthma | Chronic Obstructive Pulmonary Disease (COPD)

Taiwan
Dey

Completed

A Trial to Assess the Pharmacodynamic Response in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States
Oriel Therapeutics

Completed

Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma

Asthma

United States
GlaxoSmithKline

Completed

A 3 Way Cross-over Study Evaluating the Effects of ADOAIR Twice Daily Plus Tiotropium Bromide Once Daily Compared With the Individual Treatments of Japanese Subjects (SCO116572)

Pulmonary Disease, Chronic Obstructive

Japan
Chiesi Farmaceutici S.p.A.

Completed

A Study to Evaluate the Acute Bronchodilator Effect of CHF1535 NEXThaler

Asthma

United Kingdom
Sheffield Teaching Hospitals NHS Foundation Trust
University of Sheffield

Completed

Skin bioMARkers for Atopic Eczema Therapy Evaluation (SMART)

Atopic Eczema/Dermatitis (Non-Specific)

United Kingdom
GlaxoSmithKline

Completed

Outcomes From Initial Maintenance Therapy With Fluticasone Propionate 250/Salmeterol 50 (FSC) or Tiotropium in Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline

Completed

GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)

Pulmonary Disease, Chronic Obstructive

Japan
Mundipharma Research Limited

Completed

Efficacy and Safety of Flutiform® pMDI in Adult Patients With Mild to Moderate-severe Reversible Asthma

Asthma Bronchiale

United Kingdom
GlaxoSmithKline

Completed

Airway Hyper-responsiveness Study In Asthma Using Salmeterol/Fluticasone Propionate Combination Product

Asthma

Finland, Belgium, France, Netherlands, Sweden, Estonia, Germany, Spain, Latvia, Italy
GlaxoSmithKline

Completed

Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Australia, France, Romania, Finland, Taiwan, Bulgaria, Estonia, Canada, Netherlands, Philippines, South Africa, Sweden, Spain, Singapore, Austria, Germany, Latvia, New Zealand, China, Ukraine, Thailand, Greece, United Kingdom and more
GlaxoSmithKline

Completed

ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the GSK Group of Companies.

Pulmonary Disease, Chronic Obstructive

United States, Canada
GlaxoSmithKline

Completed

Clinical Assessment Of GW815SF Salmeterol/Fluticasone Propionate(HFA MDI) In Pediatric Patients With Bronchial Asthma -A Long Term (24-week) Study-

Bronchial Asthma

Japan
GlaxoSmithKline

Completed

WEUSRTP4850: Phase II: ICS/LABA Use in Pregnancy and Outcomes

Asthma
GlaxoSmithKline

Completed

Fluticasone Propionate-salmeterol Combination Adherence in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
SkyePharma AG
Abbott

Completed

Single-dose Crossover Study to Evaluate the Early Bronchodilating Effect of FlutiForm HFA pMDI in Adult Subjects With Mild to Moderate Asthma

Mild to Moderate Asthma

United States
Vastra Gotaland Region

Enrolling by invitation

Changes of Motor Function Tests in Congenital Myopathy Subjects Treated With Oral Salbutamol as Compared to no Treatment (COMPIS)

Musculoskeletal Diseases | Neuromuscular Diseases | Centronuclear Myopathy | Nemaline Myopathy | Congenital Myopathy | Myosin Storage Myopathy

Sweden
Université de Sherbrooke

Completed

Pharmacokinetics of Omega-3 Monoglycerides

Healthy

Canada
GlaxoSmithKline

Completed

Study Of Allergic Rhinitis In Patients Who Also Have Asthma

Asthma

United States, Estonia, Canada, Poland
Neothetics, Inc

Completed

Dose-ranging Study (LIPO-102-CL-11)

Abdominal Contour Defects

United States
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Active, not recruiting

Bioequivalence Study of Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

Asthma | Bioequivalence

Greece
John Harris

Recruiting

Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation

Allergic Contact Dermatitis | Skin Inflammation

United States
GlaxoSmithKline

Completed

Outcomes for Medicare Asthma Patients Taking Fluticasone Propionate/Salmeterol Xinafoate Combination Versus Inhaled Corticosteroids or Other Combination Therapy

Asthma

3

Subscribe